

Interline Therapeutics Raises \$92M Financing

Client News

May 13, 2021

Gunderson Dettmer represented client Interline Therapeutics, a data science and healthcare company, in its \$92 million Series Seed and Series A financing led by Foresite and Arch Ventures.

In the [announcement of the transaction](#), CEO of Interline Zachary Sweeney said, “The synergies between the technologies — from physics to biology to genetics — converged in the past five year to enable what we are doing. We think we are going to change the way drug discovery is done and change the foundation that will be expected for drug projects in the future.”

The Gunderson deal team was led by Tim Ehrlich and included Mark Foster, David Horne, Erik Thompson, Chris Crawford and Genevieve Crescenzo.

Related People



Timothy H. Ehrlich

PARTNER

P +1 617 648 9399



Mark M. Foster

PARTNER

P +1 650 463 5343



David T. Horne

PARTNER

P +1 617 648 9205

Related Services

Early-Stage Company

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding